Skip to main content

Table 4 Effects of MTX intake on laboratory parameters at last follow up

From: Methotrexate therapy impacts on red cell distribution width and its predictive value for cardiovascular events in patients with rheumatoid arthritis

  MTX-use p CV-Event p
Yes (n = 222) No (n = 163) Yes (n = 23) No (n = 362)
RDW, mean(SD), % 14,5 (1,4) 14,1 (1,6) < 0,001 15,05 (2,2) 14,25 (1,4) 0,116
Hb, mean(SD), g/l 134,8 (14,5) 132,9 (14) 0,101 130,2 (14,4) 134,2 (14,3) 0,058
CRP, mean(SD), mg/dl 0,65 (0,97) 1,03 (2,1) 0,559 0,99 (1,1) 0,8 (1,6) 0,060
ΔRDW, mean(SD) 0,53 (1,24) 0,23 (1,0) 0,057 0,45 (0,6) 0,43 (1,2) 0,809
  1. Effects of MTX intake on laboratory parameters at last visit prior to the CV event/last follow up. ΔRDW Change in RDW between initial diagnosis and follow up prior to the CV event/last follow up in patients without CV event. Hb hemoglobin level. In the overall cohort RDW at established disease was not applicable as predictive marker for a CV event. A tendency with lower hemoglobin levels and higher CRP was shown. MTX intake significantly affected RDW